Free Trial

Aerovate Therapeutics (AVTE) SEC Filings & 10K Form

Aerovate Therapeutics logo
$7.90 -0.33 (-4.01%)
As of 08/25/2025

Recent Aerovate Therapeutics SEC Filings

DateFilerForm TypeView
08/13/2025
3:26 PM
Aerovate Therapeutics (Filer)
Jade Biosciences, Inc. (Filer)
Form 8-A12B/A
07/29/2025
12:46 PM
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
VANGUARD GROUP INC (Filed by)
Form SCHEDULE 13G
07/17/2025
7:12 PM
BlackRock, Inc. (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form SCHEDULE 13G
07/14/2025
6:10 PM
Dahms Bradford D. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/14/2025
6:12 PM
Dahms Bradford D. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025
6:08 AM
Aerovate Therapeutics (Filer)
Jade Biosciences, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025
4:31 PM
Atlas Venture Associates XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2025
4:37 PM
Atlas Venture Fund XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025
3:59 PM
Atlas Venture Associates XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2025
4:03 PM
Atlas Venture Fund XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/20/2025
3:23 PM
Deep Track Capital, LP (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form SCHEDULE 13G
06/06/2025
9:03 AM
FMR LLC (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form SCHEDULE 13G
05/05/2025
8:43 AM
Frazier Life Sciences Public Fund, L.P. (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form SCHEDULE 13G
05/01/2025
5:31 PM
Fairmount Funds Management LLC (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
Form SCHEDULE 13D
05/01/2025
4:44 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Klein Lawrence Otto (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:51 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Lavelle Erin (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:58 PM
Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kiselak Tomas (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
5:00 PM
DOBMEIER ERIC (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
5:07 PM
CAIN CHRISTOPHER W. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
5:10 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Klein Lawrence Otto (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
5:15 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Lavelle Erin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
5:16 PM
Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
4:21 PM
Frohlich Tom (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:22 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Quick Jonathan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:27 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
King Andrew James (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:30 PM
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kocinsky Hetal (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:32 PM
Balta Elizabeth (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:39 PM
DOBMEIER ERIC (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
4:41 PM
CAIN CHRISTOPHER W. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/01/2025
3:22 PM
Aerovate Therapeutics (Filer)
Jade Biosciences, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2025
3:30 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/23/2025
3:37 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/21/2025
7:07 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2025
3:20 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
04/09/2025
6:00 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2025
6:01 AM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
04/07/2025
7:39 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/07/2025
7:42 AM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
04/07/2025
7:46 AM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
03/27/2025
6:30 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/26/2025
3:54 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
This stock could leave NVDA in the dust (Ad)

Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel

Click to get the full details on Eric Fry's "Nvidia alternative" right here.
03/25/2025
11:15 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form EFFECT
03/25/2025
3:25 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 424B3
03/24/2025
9:45 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form S-4/A
03/14/2025
4:16 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form S-4/A
03/03/2025
3:45 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
02/24/2025
8:57 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form S-4/A
01/24/2025
3:17 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
01/22/2025
7:45 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form S-4/A
01/13/2025
4:24 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
12/03/2024
5:27 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form S-4
Registration statement under Securities Act of 1933  
11/18/2024
4:29 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/31/2024
3:55 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/31/2024
3:55 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/31/2024
3:57 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/31/2024
3:57 PM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/31/2024
8:27 AM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2024
8:29 AM
Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
Form 425
10/17/2024
3:59 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2024
4:04 PM
Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners